Oxcarbazepinedrug info
oxcarbazepine 60 MG/ML Oral Suspension
What it is used for
Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension is indicated for:
Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures
Pediatrics: -Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years -Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective November 18, 2024. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Oxcarbazepine is an AED available as a 300 mg/5 mL (60 mg/mL) oral suspension. Oxcarbazepine is 10,11-Dihydro-10-oxo-5 H -dibenz[b,f]azepine-5-carboxamide, and its structural formula is: Oxcarbazepine USP is a light orange to creamish white or off white powder. It is sparingly soluble in chloroform, soluble in acetic acid, practically insoluble in water. Its molecular weight is 252.27 g/mol. Oxcarbazepine oral suspension, USP contains the following inactive ingredients: natural and artificial cherry flavor, colloidal silicon dioxide, malic acid, methyl paraben, noncrystallizing sorbitol solution, pregelatinized starch, propyl paraben, propylene glycol, purified water, saccharin sodium, sodium benzoate and xanthan gum. Hydrochloric acid solution or sodium hydroxide solution may be added for adjustment of pH. oxocarbazepine-os-structure
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective November 18, 2024. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance